http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yiyu Shi,Leilei Xu,Mindong Chen,Bo Yang,Ge Cheng,Cai-e Wu,Zhichao Miao,Ning Wang,Xun Hu 한국공업화학회 2022 Journal of Industrial and Engineering Chemistry Vol.105 No.-
In this work, the uniform Cu2O submicron-cubes were facilely synthesized by liquid phase reductionmethod. Then, the Cu2O submicron-cubes were further oxidized into Cu2O-CuO heterojunction with tunableCu2+/Cu+ ratios and CuO submicron-cubes by controlling the calcination temperature. The phasetransition period during calcination was real-time monitored by the in-situ XRD and in-situ DRIFTS. The obtained materials were investigated as the catalysts of CO oxidation. The results revealed thatthe Cu2O-CuO heterojunction catalysts performed much higher catalytic activities than the Cu2O andCuO counterparts. Because the synergistic effect of the heterojunction (Cu2+/Cu+) could increase the surfaceoxygen vacancy concentration. Furthermore, it was also found that only the Cu2O-CuO heterojunctionstructure with the appropriate Cu2+/Cu+ ratio behaved the optimum catalytic activity. The kineticstudies indicated that the apparent activation energy of CO oxidation was greatly affected by the Cu2+/Cu+ ratio. Therefore, these Cu2O-CuO submicron-cubes with heterostructure were considered as thepromising CO oxidation catalysts.
Weiguang Gu,Hua Zhang,Yiyu Lu,Minjing Li,Shuang Yang,Jianmiao Liang,Zhijian Ye,Zhihua Li,Minhong He,Xiaoliang Shi,Fei Wang,Dong You,Weiquan Gu,Weineng Feng 대한암학회 2023 Cancer Research and Treatment Vol.55 No.3
Purpose We aimed to evaluate whether the addition of pemetrexed is effective in improving progression-free survival (PFS) in epidermal growth factor receptor (EGFR)–mutated patients with or without concomitant alterations. Materials and Methods This multicenter clinical trial was conducted in China from June 15, 2018, to May 31, 2019. A total of 92 non–small cell lung cancer (NSCLC) patients harboring EGFR-sensitive mutations were included and divided into concomitant and non-concomitant groups. Patients in each group were randomly treated with EGFR–tyrosine kinase inhibitor (TKI) monotherapy or EGFR-TKI combined with pemetrexed in a ratio of 1:1. PFS was recorded as the primary endpoint. Results The overall median PFS of this cohort was 10.1 months. There were no significant differences in PFS between patients with and without concomitant and between patients received TKI monotherapy and TKI combined with pemetrexed (p=0.210 and p=0.085, respectively). Stratification analysis indicated that patients received TKI monotherapy had a significantly longer PFS in non-concomitant group than that in concomitant group (p=0.002). In concomitant group, patients received TKI combined with pemetrexed had a significantly longer PFS than patients received TKI monotherapy (p=0.013). Molecular dynamic analysis showed rapidly emerging EGFR T790M in patients received TKI monotherapy. EGFR mutation abundance decreased in patients received TKI combined chemotherapy, which supports better efficacy for a TKI combined chemotherapy as compared to TKI monotherapy. A good correlation between therapeutic efficacy and a change in circulating tumor DNA (ctDNA) status was found in 66% of patients, supporting the guiding role of ctDNA minimal residual disease (MRD) in NSCLC treatment. Conclusion EGFR-TKI monotherapy is applicable to EGFR-sensitive patients without concomitant alterations, while a TKI combined chemotherapy is applicable to EGFR-sensitive patients with concomitant alterations. CtDNA MRD may be a potential biomarker for predicting therapeutic efficacy.